S. 920 establishes a clinical care commission to evaluate and recommend solutions regarding better coordinating federal programs related to complex metabolic or autoimmune disorders, a disease resulting from insulin deficiency or resistance, or complications caused by any such disease. The bill requires the Commission to report its recommendations not later than three years after its first meeting. The bill sunsets the Commission at the end of fiscal year 2021.
The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress, and was published on Nov 3, 2017.
(This measure has not been amended since it was passed by the Senate on September 6, 2017. The summary of that version is repeated here.)
National Clinical Care Commission Act
(Sec. 2) This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, (4) methods for outreach and dissemination of education and awareness materials, and (5) opportunities for consolidation of overlapping federal programs.
The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.